Mon panier

Raji/Human CD19 Knockout Stable Cell Line

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
SCRAJ-STT216-2Vials (1Vial X 2)
$5355.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • Description

    The Raji/Human CD19 Knockout Stable Cell Line was generated from Raji cells through targeted knockout of human CD19 (Gene ID: 930). The expression level of human CD19 was confirmed by flow cytometry. Mutated sequences of human CD19 produced by non-homologous end joining (NHEJ) were confirmed through genomic sequencing.

  • Application

    • Useful for cell-based CD19 target-specific analysis

  • Growth Properties

    suspension

  • Selection Marker

    NA

  • Complete Growth Medium

    RPMI-1640 + 10% FBS

  • Freeze Medium

    Serum-free cell cryopreservation medium

  • Quantity

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • Storage

    Frozen in liquid nitrogen.

  • Mycoplasma Testing

    Negative

  • Sterility Testing

    Negative

  • Instructions for Use

    See data sheet for detailed culturing and assay protocol.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Receptor Assay

     CD19 FACS

    Expression analysis of human CD19 on Raji/Human CD19 Knockout Stable Cell Line by FACS.
    Cell surface staining was performed on Raji/Human CD19 Knockout Stable Cell Line using PE-labeled anti-human CD19 antibody. The Raji cells were stained with PE-labeled anti-human CD19 antibody as the positive control cell. The Raji cells were stained with PE-labeled isotype control antibody as the negative control cell.

    Protocol
  •  CD19 FACS

    Expression analysis of human CD20 on Raji/Human CD19 Knockout Stable Cell Line by FACS.
    Cell surface staining was performed on Raji/Human CD19 Knockout Stable Cell Line using PE-labeled anti-human CD20 antibody. The Raji/Human CD19 Knockout Stable Cell Line was stained with PE-labeled isotype control antibody as the negative control cell.

    Protocol
  • Sequencing Analysis

     CD19 SEQUENCING_ANALYSIS

    Genomic Sequencing of human CD19 in the Raji/Human CD19 Knockout Stable Cell Line.
    Sanger sequencing was used for mutation analysis of human CD19. The sequencing results demonstrated that frameshift mutations were generated in the human CD19 gene in the Raji/Human CD19 Knockout Stable Cell Line.

*Please contact us if you are interested in related cell pool service.

Avis des utilisateurs
Publier un commentaire

Déclaration importante

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B-lymphocyte antigen CD19

  • Catégorie:

  • Nombre de médicaments répertoriés:

    14 Détails

  • Nombre de médicaments cliniques:

    435 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Déclaration importante